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Hans H Dietrich*1, Chuanxi Xiang2, Byung H Han2, Gregory J Zipfel3 and David M Holtzman4

Abstract
Background: Evidence indicates that soluble forms of amyloid-β (Aβ) are vasoactive, which may contribute to
cerebrovascular dysfunction noted in patients with Alzheimer's Disease and cerebral amyloid angiopathy. The effects
of soluble Aβ on penetrating cerebral arterioles - the vessels most responsible for controlling cerebrovascular
resistance - have not been studied.
Results: Freshly dissolved Aβ1-40 and Aβ1-42, but not the reverse peptide Aβ40-1 constricted isolated rat penetrating
arterioles and diminished dilation to adenosine tri-phosphate (ATP). Aβ1-42 also enhanced ATP-induced vessel
constriction. Aβ1-40 diminished arteriolar myogenic response, and an anti-Aβ antibody reduced Aβ1-40 induced
arteriolar constriction. Prolonged Aβ exposure in vessels of Tg2576 mice resulted in a marked age-dependent effect on
ATP-induced vascular responses. Vessels from 6 month old Tg2576 mice had reduced vascular responses whereas these
were absent from 12 month old animals. Aβ1-40 and Aβ1-42 acutely increased production of reactive oxygen species
(ROS) in cultured rat cerebro-microvascular cells. The radical scavenger MnTBAP attenuated this Aβ-induced oxidative
stress and Aβ1-40-induced constriction in rat arterioles.
Conclusions: Our results suggest that soluble Aβ1-40 and Aβ1-42 directly affect the vasomotor regulation of isolated
rodent penetrating arterioles, and that ROS partially mediate these effects. Once insoluble Aβ deposits are present,
arteriolar reactivity is greatly diminished.

Background
Amyloid beta (Aβ) peptides are naturally occurring cleavage products of the amyloid precursor protein and produced via β- and γ-secretase resulting in soluble Aβ
monomers [1]. Important species include peptides containing 40 and 42 amino acid residues (Aβ1-40 and Aβ1-42)
[2]. Monomers of Aβ can aggregate resulting in deposits
of fibrillar Aβ both as neuritic plaques and, within blood
vessels, as cerebral amyloid angiopathy (CAA). Such
deposits are hallmarks of Alzheimer's Disease (AD) [1].
Several lines of evidence suggest that not only Aβ aggregates but soluble Aβ species may also contribute to AD
with its vasoactive properties. Cerebral hypoperfusion
prior to the onset of AD has been observed [3]. In animal
models of AD, some but not all studies suggest that solu* Correspondence: DietrichH@nsurg.wustl.edu
1 Department of Neurological Surgery, Hope Center for Neurological Disorders,

and Alzheimer's Disease Research Center, Washington University School of
Medicine, St Louis, MO, 63110, USA
Full list of author information is available at the end of the article

ble Aβ may decrease myogenic response, cerebral blood
flow (CBF) and vasodilator responses [4-10]. This implies
that soluble Aβ may have an effect on vascular regulation
possibly affecting neuronal function [5], potentially contributing to ischemic brain damage [4]. To elucidate the
vascular effects of soluble Aβ on the cerebral circulation,
studies infusing soluble Aβ into rat [11] or superfusing
mouse cortex [12] found that soluble Aβ acutely
decreased CBF and response to vasodilators, it also
increased vascular resistance and constrictor response. In
ex vivo studies, soluble Aβ causes cerebral artery constriction, reduced dilation and/or increased constriction
to endothelium-dependent dilators and vasoconstrictors,
respectively [7,12-16]. The mechanism(s) by which soluble Aβ interferes with vascular function is not fully
understood. But increased production of reactive oxygen
species (ROS) has been described [15,17-19]. However,
other mechanisms such as increased intracellular calcium
activity [16] or decreased endothelial nitric oxide availability [20] have been reported. Because endothelium-
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dependent dilation rather than smooth muscle function
[4,15] was impaired, studies concluded that soluble Aβ
causes endothelial dysfunction resulting in the observed
reduced vasomotor function [4,15,16].
To date, studies examining the functional effects of soluble Aβ on the cerebro-vasculature have been limited to
cortical CBF measurements following topical application
of soluble Aβ [12] and measurements of isolated cerebral
arteries exposed to soluble Aβ [12,20]. No data regarding
intracerebral micro-vessels exist. These vessels are
exposed to both soluble Aβ as sites of Aβ clearance [21]
and substantial CAA which forms in the vessel wall. Penetrating arterioles contribute significantly to the local
regulation of CBF by controlling as much as 25% of total
arterial resistance, exercising strong myogenic response
[22] and differ in physiological response from proximal
pial vessels and arteries [23]. For these reasons, it is
important to examine the effects of Aβ on these critical
microvessels and determine which mechanisms are
involved. Finally, the effect of prolonged exposure to
endogenous Aβ on cerebral arterioles has not been previously described.
Here we show strong effects of both soluble Aβ1-40 and
Aβ1-42 on both vasoconstriction and vasodilation in penetrating arterioles, these effects are mediated in part by
ROS. Further, prolonged exposure to high levels of Aβ in
a mouse model with CAA was accentuated with very
poor arteriolar function.

Methods
Isolation and cannulation of penetrating arterioles

All procedures were approved by the Washington University Advisory Committee for Animal Resources. Male
Sprague-Dawley rats (350-450 g, Harlan, Indianapolis,
IN) were anesthetized with pentobarbital sodium (65 mg/
kg intraperitoneally) and sacrificed. Transgenic Tg2576
mice (gift of K. Hsaio) and their wild type litter mates on
a B6/SJL background were bred in our animal facilities.
The mice were anesthetized with Ketamine/Xylazine and
sacrificed. The cerebral penetrating arterioles were
excised from the distribution of the middle cerebral
artery. Arterioles with a length of 500 to 1000 μm were
transferred to an organ bath (2.5 ml volume) mounted on
the stage of an inverted video microscope (Zeiss 100TV
or Zeiss 200), and cannulated with glass micropipettes.
No intraluminal flow was applied and the transmural
pressure was set at 50 mm Hg (mice) or 60 mmHg (rats)
and continuously monitored. We observed the internal
diameter of the vessels using a computerized diameter
tracking system (Diamtrak, T.O. Neild, Flinders University, Adelaide, Australia) with a spatial resolution of 0.5
μm/pixel and a data acquisition rate of 10 Hz. Rat arterioles averaged a maximum passive diameter of 64.9 ± 13.6
μm. Mouse arterioles averaged maximum passive diame-
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ters of 51.8 ± 7.7 μm for WT littermates and 52.7 ± 7.0
μm for APPsw mice.
The arterioles were superfused continuously with a
physiological saline solution (37.5°C; pH 7.3) of the following composition (in mmol/L): 144 NaCl, 3 KCl, 2.5
CaCl2, 1.4 MgSO4, 2.0 pyruvate, 5.0 glucose, 0.02 ethylenediaminetetraacetic acid (EDTA), and 2.0 3-(N-morpholino) propanesulfonic acid (MOPS), 1.21 NaH2PO4.
After equilibration, the vessels developed spontaneous
tone and we confirmed their viability by changing the
extraluminal pH from 7.3 to 6.8 and from 7.3 to 7.65. Vessels with poor tone (less than 20% decrease from the
maximum diameter) or poor response to pH (less than
15% change in diameter after pH change) were excluded.
Pharmacological studies

Stock solutions of commercially available amyloid β peptides were prepared in distilled water (one mmol/L), kept
frozen until use and diluted in physiological buffer just
prior to use. Using Western blot, we confirmed that the
preparations contained predominantly monomeric peptides (data not shown). Similarly, adenosine tri-phosphate
(ATP) stock was prepared in distilled water (10 mmol/L)
and kept frozen until use. Mn(III) tetrakis (4-benzoic
acid) porphyrin (MnTBAP), catalase and superoxide dismutase (SOD) were used to scavenge oxygen radicals. For
dose response or agonist studies, the vessel where pretreated with respective Aβ concentrations for 20 minutes.
Agonists such as ATP where applied in the presence of
amyloid β. Purinergic P2X1 receptors were inhibited with
pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid
(PPADS, 3 μmol/L) [24].
Amyloid peptides were purchased from American Peptide Co. (Sunnyvale, CA); all other chemicals were
obtained from Sigma (St. Louis, MO).
CAA coverage on TG2576 mouse cerebral arterioles
was visualized according to our previously published
method using Thioflavin-S (0.005% in MOPS buffer) to
visualize CAA. Qualitatively, the vessels in this study
were affected to the same extent by CAA as was shown in
our previous publication [8].
Cell Culture

Rat cerebral microvascular endothelial and smooth muscle cell lines (obtained from Dr. Diglio, Wayne State University, Michigan) [25,26] were cultured in antibiotic free
DMEM with 10% FCS at 37°C at 95% CO2 and 5% air.
Though cell cultures may have undergone changes compared to native cells, in preliminary experiments we confirmed that the endothelial cells tested positive for
endothelial nitric oxide and the smooth muscle cells for factin thus retaining their respective main phenotype. Cell
suspensions were plated into 96 well plates and grown to
near confluency. On the day of experiment, the cells were
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washed with warmed (37°C) Medium Leibovitz, loaded
with the oxygen radical sensitive dye MitoTracker Red
CM-H2XRos (Invtirogen, diluted in Medium Leibovitz at
5 μmol/L) and incubated for 15 to 20 minutes. After incubation, the cells were washed with warmed Medium Leibovitz, freshly dissolved Aβ was added (one and two
μmol/L) immediately before the measurement and the
change in fluorescence measured for 30 minutes at 37°C
with a plate reader (Synergy HTTR with KC4 software,
Biotek Instruments, Ex = 475 ± 15 nm, Em = 645 ± 40
nm). Oxidation of MitoTracker Red CM-H2XRos by ROS
increases the dye's fluorescence 100-fold rendering it very
sensitive as a detector of ROS. In preliminary experiments we also tested 100 nM Aβ which had insignificant
effect and was not used further.
Statistics

All data are presented as mean ± SEM, with n representing the number of observations. Statistics were conducted on absolute vessel diameters. Differences were
considered significant at p < 0.05 and determined by
repeated-measures analysis of variance RANOVA with
Student-Newman-Keuls test as post test or paired Student's t-test where appropriate. For the Aβ dose response
studies, the data are presented as relative diameter
change (% relative vessel Diameter = DATP/DTone *100)
where DTone is the baseline diameter of the vessel before
the stimulation with ATP, and DATP is the diameter of the
vessel after the stimulation. For experiments with Aβ preincubation and mouse vessels the data are presented as
percent maximal diameter and was calculated by the following formula: % maximum dilation = [(DATP - Dtone)/
(Dmax - Dtone)]* 100, where Dmax is the maximum diameter
of the vessel at 60 mm Hg before the development of
spontaneous tone [24,27]. This method corrects for
changes in arteriolar to due to Aβ incubation. Changes in
fluorescence intensity are presented as percent change
from time zero time over 30 minutes of observation time.

Results
Extraluminal application of soluble Aβ1-40, Aβ1-42 the
reverse peptide Aβ40-1 on arteriolar tone and myogenic
response

Rat penetrating cerebral arterioles exposed to Aβ1-40 had
a maximum diameter of 63.2 ± 4.1 um and developed a
spontaneous tone diameter of 46.9 ± 3.3 um (n = 8).
Freshly dissolved Aβ1-40 resulted in constriction of penetrating arterioles in a dose dependent manner which was
significant at a concentration of 0.1 and 1 μmol/L resulting in a reduction of the tone diameter by 26.3 ± 2.9%
(Figure 1A).
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Vessel exposed to Aβ1-42 had a maximum passive diameter of 78.0 ± 8.7 μm and developed a spontaneous tone
diameter of 56.8 ± 7.1 μm. Freshly dissolved Aβ1-42 constricted the penetrating arterioles significantly at 0.1 and
1μmol/L, an effect similar to that seen with Aβ1-40 (Figure
1A). However, at one μmol/L Aβ1-40, there was a 13%
stronger constriction compared to Aβ1-42 (p < 0.05).
Vessels treated with the reverse peptide Aβ40-1 had a
maximum diameter of 64.8 ± 7.2 μm and a spontaneous
tone diameter of 46.6 ± 5.6 μm (n = 4). The reverse peptide had no effect on the tone diameter (Figure 1A).
Myogenic response describes the ability of arterial
blood vessels to maintain a constant vessel tone over a
range of intraluminal pressures, a mechanism important
for cerebral autoregulation. The arterioles used had a
maximum diameter of 76.5 ± 13.5 μm and a tone diameter of 60.7 ± 10.7 μm before and of 51.5 ± 9.3 μm after
Aβ1-40 (0.1 μmol/L). Under control conditions, vessels
maintained their diameter as intraluminal pressure
increased from 60 mmHg to 90 mmHg and 120 mmHg.
After incubation with freshly dissolved Aβ1-40 (0.1 μmol/
L) the vessels' ability to maintain myogenic responses was
eliminated at 120 mmHg intraluminal pressure but not at
90 mmHg. The vessels returned to base line diameters at
60 mmHg indicating that the pressure increase did not
permanently damage the vessels (Figure 1B).
Arteriolar response to adenosine tri-phosphate (ATP) and
soluble Aβ1-40 and Aβ1-42

Extraluminal ATP causes a biphasic vessel response with
a transient constriction caused by smooth muscle P2X1receptors and a subsequent endothelium dependent dilation via P2Y-receptors [24] thus allowing studies of both
smooth muscle- and endothelium-dependent responses.
We confirmed that ATP causes a transient constriction
via P2X1 stimulation in mouse cerebral arterioles. PPADS
(3 μmol/L) significantly inhibited constriction to ATP
(100 μmol/L) from -16.6 ± 1.2% to -1.3 ± 0.7% (n = 3)
while dilation to ATP was unchanged (data not shown).
Arterioles treated with Aβ1-40 had a passive maximum
diameter of 58.6 ± 3.7 μm and spontaneously constricted
to 41.2 ± 3.6 μm (n = 5). Vessels treated with Aβ1-42 had a
maximum diameter of 69.5 ± 5.4 and a tone diameter of
48.2 ± 4.1 μm. Both freshly dissolved Aβ1-40 and Aβ1-42
(one μmol/L) significantly decreased dilation to ATP
indicating that endothelium dependent dilation was
reduced (Figure 1C and 1D). While the constrictory
response to ATP was unchanged in the presence of Aβ140, we observed an enhanced smooth muscle-dependent
constriction with Aβ1-42 with 100 μmol/L concentrations
of ATP (Figure 1D). Repeated application of ATP alone
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Figure 1 Effect of freshly dissolved Aβ on rat penetrating arteriolar vessel tone, myogenic response and effect on ATP induced vasomotor
responses. Cerebral arterioles ex vivo were treated with increasing concentrations of Aβ1-40, Aβ1-42 or reverse peptide Aβ40-1 and the effect on arteriolar
tone measured. (A)Aβ1-42 constricts the arterioles similarly to Aβ1-40 at 0.1 μmol/L while at 1 μmol/L Aβ1-40 has a greater effect. * and ! denote p < 0.05
from control (ANOVA). The reverse peptide Aβ1-40 had no effect. (B) Arterioles pretreated with Aβ1-40 (0.1 μmol/L) lose myogenic response at 120
mmHg intraluminal pressure. Returning to 60 mmHg baseline pressure reestablished control tone diameter. * denotes p < 0.05 from control (n = 3
vessels). Cerebral arterioles were treated with Aβ and vasomotor responses to extraluminal ATP were observed. (C) Aβ1-40 and (D) Aβ1-42 reduce vasodilation to ATP at 1 and 100 μmol/L concentrations. In addition Aβ1-42 also enhances constriction at 100 μmol/L ATP. * denotes p < 0.05 between before and after amyloid peptide (ANOVA).

(100 μmol/L) did not change the vessel response (relative
first constriction of -66.6 ± 7.1% and dilation of 46.2 ±
5.4% versus repeated constriction of -53.2 ± 6.4% and 39.2
± 7.2% dilation, n = 4 vessel, repeated measures ANOVA).
Soluble Aβ and ROS

Soluble Aβ may cause ROS production in cerebral vessels. We applied the reactive oxygen scavenger MnTBAP
(1 to 100 μmol/L) and found that in the presence of Aβ1-40
(1 μmol/L) MnTBAP partially restored vessel tone and
diameter at the highest MnTBAP concentration (Figure
2). MnTBAP itself had no effect on the vessel diameter.

Microvascular endothelial and smooth muscle cells, Aβ1-40
and Aβ1-42 and ROS

To study a possible contribution of reactive oxygen species in the observed vessel dysfunction, we loaded cultured rat cerebral microvascular endothelial or smooth
muscle cells with the ROS sensitive dye MitoTracker Red
CM-H2XRos. We found that after 30 minutes of incubation, both freshly dissolved Aβ1-40 and Aβ1-42 significantly
and dose dependently increased ROS production in the
two cell types with Aβ1-42 having a greater effect in
endothelial cells compared Aβ1-40 (Figure 3A and 3B). In
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Figure 2 Attenuation of Aβ1-40-induced vessel constriction by
ROS scavenging. Cerebral arterioles were incubated with 100 nmol/L
Aβ1-40 and/or the ROS scavenger MnTBAP. MnTBAP reduced Aβ1-40-induced vessel constriction at 100 μmol/L indicating that the Aβ effect is
partially due to reactive oxygen species. * denotes p < 0.05 from Aβ
alone (n = 3). MnTBAP itself had no effect on the vessel diameter (n =
5).

smooth muscle cells, Aβ1-42 was more effective at 1 μmol/
L than Aβ1-40 in producing ROS (Figure 3C and 3D). Aβ
(100 nM) induced production of ROS was inhibited by
the ROS scavenger MnTBAP (Figure 4), but not by SOD
(60 U/ml, Figure 5) or Catalase (40 U/ml, data not
shown). These data correspond with our ex vivo observation that MnTBAP reduces the effect of Aβ indicating
that ROS are involved in the observed vascular dysfunction. However, it is possible that cultured cells may not
correctly reflect in vivo situations.
Arteriolar vasomotor responses and chronic exposure to
soluble Aβ

We compared vasomotor responses to ATP ex vivo in
penetrating arterioles from Tg2576 mice of 3, 6 and 12
months of age compared to age matched wild type littermates. Tg2576 mice develop Aβ deposition in the brain
and arterioles beginning at 9 months of age [28,29]. Wild
type vessels had maximum diameter of 53.5 ± 6.5 μm,
61.8 ± 3.6 μm and 54.8 ± 5.3 μm at 3, 6 and 12 months of
age, respectively. The tone development was 16.5 ± 6.5 ±
1.2% (n = 24), 13.3 ± 2.9% (n = 4) and 9.8 ± 6.2% (n = 4).
Vessels from Tg2576 mice had a maximum diameter of
54.0 ± 3.5 μm, 55.8 ± 2.8 μm and 54.6 ± 2.6 μm at 3, 6 and
12 months of age, respectively. The tone development
was 6.8 ± 0.5% (n = 3), 26.5 ± 8.0% (n = 4) and 1.8 ± 1.4%
(n = 6). We found no difference in the responses to ATP 3
at months (Figure 6A). At six months of age dilatory
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response to ATP was reduced in the Tg2576 vessels compared to wild type vessels. At 12 months of age, both dilatory and constrictory vasomotor responses to ATP were
virtually absent in Tg2576 vessels while the wild type vessels still showed a constriction to ATP followed by a small
dilation (Figure 6A). We measured amyloid coverage in
three vessels which was 67.9 ± 4.0%. To test if the vessels
from the 12 month old Tg2576 mice can respond to other
vasoactive stimuli, we applied alkaline buffer of pH 7.65
and observed a constriction of 10.9 ± 5.2%, indicating
that the arterioles still have some capacity to respond
other stimuli.
Extraluminal application of anti-Aβ antibody 4G8

Passive immunization with certain anti Aβ antibodies has
shown that such treatment can rapidly improve cognitive
function in animal models of AD [30]. We tested the
hypothesis that antibody treatment can interfere with the
effect of soluble Aβ on cerebral arterioles. Arterioles were
first treated with freshly dissolved Aβ1-40, the Aβ washed
out, treated with the anti-Aβ antibody 4G8 antibody
(1:200 dilution) and finally the 4G8 washed out. Each
treatment applied for 30 minutes and the diameter measured at the end of each treatment. Freshly dissolved Aβ140 significantly constricted the arterioles and this constriction remained even after 30 minutes of washout.
Incubation with 4G8 antibody with the vessels, 30 minutes after Aβ1-40 washout, restored vessel tone (Figure
6B). For control experiments we replaced 4G8 antibody
with non-specific IgG antibody. In this control experiment non-specific IgG did not restore vessel tone showing that Aβ1-40 has a prolonged vasoconstrictive effect
even after prolonged washout (Figure 6B). This indicates
that Aβ1-40 may interact with the vessel even after washout and that antibody to soluble Aβ may interfere with
this interaction.

Discussion
Our study has several notable findings, including the following: 1) freshly dissolved Aβ1-40 and Aβ1-42, but not the
reverse peptide Aβ40-1, acutely increase vessel tone in rat
cerebral penetrating arterioles, with Aβ1-42 being equally
potent to Aβ1-40 except at the highest concentration; 2)
Aβ1-40 and Aβ1-42 both decrease endothelium-dependent
dilation to ATP, with Aβ1-42 also enhancing smooth muscle dependent constriction; 3) Aβ1-40 decreases arteriolar
myogenic response; 4) MnTBAP attenuates Aβ1-40induced increase in vessel tone increase suggesting that
reactive oxygen species have a contributing role in Aβinduced enhancement in vessel tone; 5) Aβ1-40 and Aβ1-42
acutely increased ROS production in cultured rat cerebral
microvascular endothelial and smooth muscle cells in a
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Figure 3 Dose dependent increase of oxygen radical production induced by soluble Aβ in cultured rat cerebral microvascular cells. To quantify Aβ-induced ROS production in vascular cells, rat cerebral microvascular endothelial and smooth muscle cells were incubated with soluble Aβ (1
and 2 μmol/L) and ROS production was measure using the ROS sensitive dye MitoTracker Red CM-H2XRos (5 μmol/L). (A) Aβ1-40 and (B) Aβ1-42 increase
dose-dependently ROS in endothelial ECs) and (C and D) smooth muscle cells (SMCs). * denotes p < 0.05 from control. In SMCs Aβ1-42 has a stronger
effect compared to Aβ1-40 as indicated by † = p < 0.05. N ≥ four replicates with four cultures per replicate (n ≥ 16). n.s. denotes not significant.

dose dependent fashion - a response that was inhibited by
the cell permeable ROS scavenger MnTBAP but not SOD
or catalase; 6) Incubation of penetrating arterioles with
Aβ1-40 for 30 minutes resulted in prolonged increased
tone which was not restored by Aβ washout but was
restored by the anti-Aβ antibody, 4G8; and 7) exposure to
soluble as well as deposited Aβ decreased vascular reactivity over time in arterioles from Tg2576 mice, an animal

model of AD. These results confirm many previous
reports but also extend our understanding of the vascular
effects of soluble Aβ, especially in regards to the pathological effects of Aβ1-42 on vessels and vascular cells.
These results indicate a direct effect of the studied Aβ
species on cerebral penetrating arterioles with potentially
important differences in their activity such as enhanced
arteriolar vasoconstriction to ATP or increased ROS pro-
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Figure 4 Scavenging of oxygen radical production in rat cerebral
microvascular endothelial and smooth muscle cells. ROS production was measured in rat cerebral microvascular endothelial and
smooth muscle cells using the ROS sensitive dye MitoTracker Red CMH2XRos (5 μmol/L). MnTBAP (100 μmol/L) inhibits the increase in (A)
Aβ1-40- and (B) Aβ1-42-induced oxygen radical production both in cultured rat cerebral microvascular endothelial cells and in smooth muscle cells (C and D). † denotes p > 0.05 from Control; * denotes p > 0.05
MnTBAP versus respective Control (ANOVA). N > three replicates with
three cultures per replicate (n ≥ 9).

duction by Aβ1-42 but increased vessel constriction by
Aβ1-40.
The penetrating cerebral arteriole is an important regulator of CBF representing about 25% of the total cerebral
arterial regulatory capacity. Further, it is the part of the
cerebral circulation most profoundly involved in the trafficking of Aβ from the brain [21] and continuously
exposed to Aβ. Though the concentration of Aβ in the
CSF is in the nanomolar range [31] the concentration in
the periarteriolar space is not known and could be higher
especially when transport across the arteriole is compromised and Aβ accumulates. Such accumulation would
eventually lead to CAA [32]. So far no study has directly
addresses the effect of soluble Aβ in this essential
microvessel.

In CAA, amyloid deposition consists predominantly of
Aβ1-40 rather than Aβ1-42 species [33]; however, in most
cases of CAA, Aβ1-42 may initially be necessary to induce
amyloid deposition [34]. Thus initial studies related to the
effect of freshly dissolved Aβ on cerebral vessels that concentrated on Aβ1-40 [15]. Niwa et al. directly compared
the effects of soluble Aβ1-40 versus Aβ1-42 in mouse cerebral circulation and found that Aβ1-40 but not Aβ1-42 recapitulated the observed vascular dysfunction in a mouse
model of AD with a high Aβ1-40 to Aβ1-42 ratio [5,6,8].
Similarly, in rat aorta, Aβ1-42 was less effective than Aβ1-40
[35]. Our data indicate that at concentrations up to 100
nmol/L both Aβ species have a similar effect on rat cerebral arteriolar tone (though at concentrations higher than
100 nmol/L Aβ1-40 produced greater arteriolar tone). Previous studies found that Aβ1-40 reduced endothelium dilation to variety of agonists as well as physiological whisker
stimulation [15,19] while Aβ1-42 and the reverse peptide
Aβ40-1 did not [5,6,12]. Adenosine tri-phosphate (ATP) is
an important cerebral vasoactive agonist which can be
released from numerous sources including cerebral purinergic nerves, astrocytes and red blood cells [36].
Extraluminally applied ATP causes a biphasic diameter
response in cerebral arterioles with an initial transient
constriction due to smooth muscle cells purinergic P2X1receptors [24,36] which quickly desensitize [37] followed
by an endothelium-dependent dilation via P2Y-receptors
[24,36]. The effect of Aβ species on ATP-induced vasomotor responses has not been reported previously. We
found that similar to other endothelium-dependent agonists, Aβ1-40 and Aβ1-42 reduce dilation to ATP. Agonistinduced constriction with endothelin or serotonin is
increased after Aβ1-40 [15]; however, this enhanced constriction was attributed to decreased endothelial function
rather than an effect on smooth muscle cells [5,6,15]. In
mice intraluminal Aβ1-40 caused an endothelin-dependent decrease in CBF which was attenuated by inhibiting
the receptor for advanced glycation end products (RAGE)
[38]. In our study we found that Aβ1-42 but not Aβ1-40
enhances constriction to ATP. This constrictive response
to ATP is mediated via smooth muscle cells (endothelial
denudation does not affect ATP-induced vasoconstriction [36]) and is likely due to desensitization of the P2X1receptor responsible for constriction by limiting the time
of its activity [36]. The enhanced constriction observed
with Aβ1-42 likely means that it has a direct effect on
smooth muscle cell function either by Aβ1-42 prolonging
the open probability of the P2X1-receptor or by enhancing
the sensitivity of the smooth muscle contractile apparatus. Freshly dissolved Aβ1-40 also decreases arteriolar
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Figure 5 Effect of superoxide dismutase (SOD) on Aβ-induced ROS increase. ROS production was measured in rat cerebral microvascular endothelial and smooth muscle cells using the ROS sensitive dye MitoTracker Red CM-H2XRos (5 μmol/L). SOD was unable to attenuate Aβ1-40-induced
reactive oxygen radical increase in either (A) endothelial (ECs) or (B) smooth muscle cells (SMCs). * denotes p > 0.05 from Control. N > three replicates
with three cultures per replicate (n ≥ 9).

myogenic response. That increased Aβ may decrease
myogenic response was shown in a mouse model of AD
[6].
Passive immunization with anti-Aβ antibodies is being
evaluated as a possible treatment for AD [39]. Dodart et
al. showed that passive immunization could rapidly
(within 24 to 72 hours) improve cognitive function in an
animal model of AD [30]. We therefore hypothesized that
an antibody against Aβ may rapidly ameliorate Aβinduced increase in arteriolar tone. We found that a 30
minute incubation with Aβ1-40 resulted in a persistent (>
90 minutes) increase in arteriolar tone despite repeated
washouts. This indicates that, once in contact with the
vessel, Aβ1-40 retains its vasoactive effect even in the
absence of extravascular Aβ for some time. However,
after application of the anti-Aβ antibody 4G8, the arteriolar tone was restored while non-specific IgG had no
effect. This observation is consistent with the notion that
Aβ1-40 resides on the cell surface in such a way that only
high affinity binding agents can remove or neutralize.
Alternatively the Aβ signaling mechanism may be slow to
come on and slow to turn off. Further studies are needed
to resolve the mechanism of soluble Aβ-induced arteriolar dysfunction. Taken together we present for the first
time evidence that soluble Aβ1-40 as well as Aβ1-42 directly
impair cerebral penetrating arteriolar function and that
Aβ1-42 may be considered a vasoactive Aβ species in this
preparation.

ROS

The mechanism behind cerebral vascular dysfunction
due to soluble Aβ is not completely understood. There is
evidence that ROS are involved [15,17-19]. Since peroxynitrite did not duplicate soluble Aβ-induced vascular
dysfunction in rat aorta [17], superoxide anion produced
by NADPH oxidase may contribute to the observed vascular dysfunction [17,18]. Other studies suggest that soluble Aβ causes activation of COX-2 and other
inflammatory responses resulting in the observed vascular dysfunction [13,40]. Soluble Aβ may trigger intracellular calcium mobilization which may activate calcium
sensitive PKCs resulting in deactivation of eNOS [16].
We applied the cell permeant oxygen radical scavenger
MnTBAP to cerebral arterioles ex vivo and found a partial
restoration of arteriolar tone, indicating that oxygen radicals contribute to the increased tone development by Aβ.
To further elucidate the acute effect of freshly dissolved
Aβ on vascular cells, we measured ROS production in rat
cerebro-microvascular endothelial and smooth muscle
cells. Our results show, that freshly dissolved Aβ1-40 and
Aβ1-42 dose-dependently increase ROS production in
both endothelial and smooth muscle cells with Aβ1-42
having a greater ability to induce oxygen radical formation. This indicates that both Aβ species may acutely
interfere with either cell type and their function in vascular regulation. Studies show that extraluminal Aβ1-40
damages cerebrovascular endothelium and impairs function within 30 minutes of incubation [15,40] indicating
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Figure 6 Vasomotor responses to ATP in penetrating arterioles of 3, 6 and 12 months old Tg2576 and WT litter mates and attenuation of
Aβ1-40 induced vessel constriction by 4G8 antibody. Vasomotor responses to extraluminal ATP were measured in cerebral arterioles of control littermate and TG2576 mice ex vivo. (A) At three months of age, the vessels show strong responsiveness to extraluminal ATP both in Tg2576 and WTLM. At six months, dilation to ATP is reduced in Tg2576 mice. At 12 months, vasomotor responses in Tg2576 vessels are greatly reduced and the vessels
show smooth muscle cells enveloped by amyloid. Insert: Thioflavin-S staining of an arteriole (44 μm diameter) from a Tg2576 mouse used in the experiments. * denotes p > 0.05 from WT at same age. (B) Incubation with Aβ1-40 caused a significant arteriolar constriction which lasted at least for 30
minutes after washout. The soluble Aβ-specific antibody 4G8 restored control vessel tone while the control IgG did not. * = p < 0.05 from tone diameter for both control IgG and 4G8 treated vessels; t = p < 0.05 from Aβ1-40-induced constriction; n.s = not significant from Aβ1-40-induced constriction.

that Aβ quickly reacts with vascular cells. This suggests
that Aβ may reach the abluminal endothelium to exert a
direct endothelial effect similar to other small peptides
such as bradykinin. While we and others found that Aβ
directly affects endothelial cells in culture, experiments
with extraluminal Aβ application are not consistent as to
whether extraluminal Aβ directly affects the endothelium
or if the Aβ effect is limited to the vascular smooth muscle from which a noxious mediator may diffuse to the
endothelium. Catalase and superoxide dismutase (SOD)
did not affect the Aβ-induced ROS production. MnTBAP
is a cell permeable SOD-mimetic, as such MnTBAP scavenges O2- at the source, presumably the mitochondria.
SOD is not cell permeant and O2- does not diffuse well
out of the cell due to its polarity. As such SOD is expected
to have less or no effect of scavenging intracellular ROS.
Catalase metabolizes H2O2 to H2O and O2-. H2O2 is cell
permeant and could be metabolized by extracellular catalase. However, since catalase did not change the ROS signal, H2O2 may not be involved in the observed ROS

production. No study on the acute effect of Aβ-induced
ROS on cerebral microvascular endothelial cells in vitro
exists though cytotoxicity following a 24 hour exposure of
cells incubated with Aβ1-40, was reduced by MnTBAP in
RBE4 cells indicating that ROS were produced [17]. A
consequence of oxidative stress is increased lipid peroxidation, measured e.g. as thiobarbituric acid reactive substances (TBARS), which was increased in cultured
astrocytes after 24 hour incubation with Aβ1-40 [41].
While we were able to detect an increase in ROS with
MitoTracker Red CM-H2XRos fluorescence, in preliminary experiments we could not detect an increase in lipid
peroxidation with thirty minutes of Aβ incubation. It is
likely that this incubation time is not long enough to
result in a lipid peroxidation detectable by the TBARS
method and more sensitive approaches such a mass spectroscopy have to be used.
Though no observations for acute effects exist, differences in the effect of Aβ species on endothelial cells were
found in several studies. Folin et al. found that Aβ1-40 was
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less toxic to neuro-endothelial cells than Aβ1-42 [42] while
the opposite was found for human cerebrovascular
endothelial cells [43]. In other vascular endothelial cells it
was found that Aβ1-40 reduces production of nitric oxide
[16,20]. The effect of the vasculotropic Dutch (E693Q)/
Iowa (D694N) mutant human Aβ1-40D was studied in
human cerebro-vascular smooth muscle cells. The study
found that Aβ1-40D did not increase ROS production [44].
Other mechanisms such as increased intracellular calcium activity [16] or decreased endothelial nitric oxide
availability [20] have been reported which could also contribute to the observed vascular dysfunction.
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Tg2576 animals. Relative CBF was found to be decreased
in 13 month old Tg2576 mice [7]. CBF responses to a
variety of stimuli in Tg2576 mice of 8 months (pre-CAA)
was not different from age matched controls though they
were depressed in 19 month old animals [9,10]. While our
and the above studies did not observe vascular anomalies
in Tg2576 mice younger than 6 months of age, Niwa et al.
found decreased CBF responses in young (two to three
months) Tg2576 mice [6]. It should be noted, however,
that our data at 3 months of age did show a trend for
decreased dilation and increased vasoconstriction in
Tg2576 mice indicating that increased Aβ may have
begun to effect cerebral arteriole function early in life.

Chronic exposure to soluble Aβ

To test if chronic exposure to increased Aβ levels affects
arteriolar vasomotor function over time, we compared
arteriolar diameter responses of vessels from Tg2576
mice, a commonly used AD mouse model having elevated
levels of soluble Aβ throughout life and age-dependent
development of CAA [28], with age matched littermate
controls. We found no difference in vessel responses to
ATP at three months of age, but at six months of age, dilation to ATP was reduced in Tg2576 mice. There was also
a trend towards increased tone and increased ATPinduced vasoconstriction, but this did not reach statistical significance. In 12 month old Tg2576 mice, the vasomotor response to ATP was essentially absent.
Stimulation with alkaline pH still resulted in some constriction indicating that the vessels were responsive to
some physiological stimulus. At this age, the vessels evaluated had CAA coverage of approximately 67%. Amyloid
can also be sequestered in the basement membrane
[45,46] which may be more likely to occur with basement
membrane thickening that occurs with age. This will
affect vessel functionality. Further accumulation of soluble Aβ could lead to formation of Aβ oligomers which in
some studies are shown to be more effective/toxic than
monomeric soluble Aβ [47]. The possible effect of Aβ oligomers on cerebral arterioles will be important to assess
in future experiments. The lack of vasodilation in these
vessels corresponds well with in vivo observations in pial
arterioles where a CAA coverage of 50% or more eliminated dilatory response to hypercapnia [8]. The same
study also found that in 12 month old TG2576 vessels, the
smooth muscle content was significantly reduced. Thus
increased CAA coverage and decreased smooth muscle
content could, in part, explain the weak constrictory
response observed at this age in our ex vivo studies.
Taken together these findings indicate that on the arteriolar level, chronic exposure to Aβ may lead to alterations in vasomotor function as early as six months of age
when no amyloid deposits are present [5,8]. Though vessel function decreases with age, it deteriorates severely in

Conclusions
Utilizing isolated rat cerebral arterioles ex vivo, we found
that both Aβ1-40 and Aβ1-42 cause vessel constriction and
reduced dilation to ATP, with Aβ1-42 also enhancing arteriolar constriction response. Together with the observed
loss of myogenic response, increased soluble Aβ levels
may lead to pronounced vessel dysfunction in vivo. Both
Aβ1-40 and Aβ1-42 increased oxygen radical production in
cerebro-microvascular endothelial and smooth muscle
cells which was inhibited by MnTBAP, indicating that
oxygen radicals, in part, contribute to Aβ-induced penetrating arteriole dysfunction. The effects of Aβ-incubation on cerebral arterioles persists after washout but can
be alleviated with an anti-Aβ antibody, suggesting that Aβ
may exert its effects while bound to the cell surface.
Chronic exposure to elevated Aβ results in cerebral
microvascular dysfunction before CAA at six months of
age which worsened with age resulting in minimal
responsiveness at 12 months with CAA present. Overall
the results suggest that soluble and fibrillar Aβ is influencing arteriolar function which may have an important
effect on brain dysfunction in AD and CAA and may contribute to ischemia.
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